APG-2449 is a novel FAK inhibitor and a third-generation ALK/ROS1-TKI that has shown potent activity towards a range of ALK-resistant mutations and brain penetrant capacity in pre-clinical NSCLC tumor models. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.